INS and type 2 diabetes mellitus: It is understood that the pathophysiology of T2D differs between Asian populations and non‐Asian populations,15, 36 and the ratio of iGlar and Lixi in the iGlarLixi pen‐injector used in Soli‐D (maximum 40 U/day of insulin) differs from that of the studies in the current NMA (maximum of 60 U/day of insulin).16, 17